- French biotech Onxeo ( OTC:OXNXF ) on Thursday said the U.S. FDA had cleared its initial investigational new drug (IND) application for its oncology drug AsiDNA.
- OXNXF can now start a phase 1b/2 trial to evaluate AsiDNA in combination with olaparib (a type of targeted cancer drug known as a PARP inhibitor) for the treatment of ovarian, breast and prostate cancer patients who have shown improvement with previous PARP inhibitor treatment.
- The company said it plans to start the trial in H2 2022 at three to five potential clinical sites across the U.S.
- Onxeo added that this was its first U.S. IND filed since its U.S. team came on board in April.
For further details see:
FDA clears Onxeo to start phase 1b/2 trial in the U.S. of its oncology drug AsiDNA